NIH T-32 Postdoctoral Fellow Clinical Pharmacology
Thomas Jefferson University
Viren Soni graduated from Rowan University in 2024
with a Ph.D. in Pharmaceutical Chemistry with a
specialization in Medicinal Chemistry under the
guidance of Dr. Subash C. Jonnalagadda, Ph.D. and
Kandalam V. Ramanurajchary, Ph.D., Rowan
University, Glassboro, NJ, USA. His Ph.D. Thesis
work was on the Development of Novel Salinomycin
Derivatives as Potential Anticancer Agents.
Viren is currently an NIH T-32 Postdoctoral Fellow in
Departments of Pharmacology, Physiology and Cancer
Biology as well as Pharmaceutical Sciences at Thomas
Jefferson University, working under the guidance of
Dr. Walter Kraft, M.D. and Dr. Gagan Kaushal, Ph.D.
Dr. Soni’s work on Salinomycin thus far has been
published in the International Journal of Translational
Medicine entitled A Concise Review of Prodigious
Salinomycin and Its Derivatives Effective in Treatment
of Breast Cancer: (2012–2022). His other work on
Benzoboroxales is under review for publication by the
Journal of Medicinal Chemistry: Harnessing the
Potential of Benzoxaborole Compounds for Next-
Generation Therapeutics and Beyond.
The current work during his Postdoctoral Fellowship
that are published are titled: Long-term
stability, sterility, and cost-effectiveness of 0.05%
chlorhexidine gluconate as antisepsis for intravitreal
injection submitted to the Journal of Ocular
Pharmacology and Therapeutics; Azithromycin Dosing
and Preterm premature rupture of membranes
Treatment (ADAPT): A randomized controlled Phase I
trial, published in the American Journal of Obstetrics
and Gynecology MFM.
He has presented at various conferences such as the
ADA Foundation Research Conference in Bethesda
MD, ICMAT Conference in Singapore, AAPSNERDG
in Connecticut, and the ICUMSAT
conference at Telangana University, Nizamabad, India,
to name a few.